Interim Report January - June 2026
Interim Report January - June 2026
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
18 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Interim report January — June 2026
Interim report January — June 2026
Xintela AB files interim report for Jan–Jun 2026
Xintela AB released its interim report for January to June 2026.
KDVB Interim Report for January–June 2026
KDVB issued an interim report covering January–June 2026.
Pila Pharma publishes interim report for H1 2026
Pila Pharma has published its interim report covering 1 January to 30 June 2026.
Resurs Bank releases interim report for Jan–June 2026
Resurs Bank has published its interim report covering January–June 2026.
BioInvent International AB interim report covers Jan–June 2026
BioInvent International AB published its interim report for January–June 2026.
Resurs Holding interim report for Jan–Jun 2026
Resurs Holding published its interim report for the January–June 2026 period.
OncoZenge AB files interim report for Jan 1–Jun 30, 2026
OncoZenge AB released an interim report covering January 1 through June 30, 2026.
Pamica Group AB releases interim report for Jan–Jun 2026
Pamica Group AB published its interim report for January–June 2026.
Interim Report January—June 2026
Interim Report January—June 2026
Scandinavian Tobacco interim update: Focus2030 progress, 2026 guidance maintained
Scandinavian Tobacco Group said it is progressing with Focus2030 and maintained full-year 2026 guidance in its interim report for 1 January–30 June 2026.
Interim report for the period 1 January — 30 June 2026
Interim report for the period 1 January — 30 June 2026
IRLAB publishes interim report for January–June 2026
IRLAB published its interim report covering the period January to June 2026, according to TradeXchange Newsdesk.
SEYE SMTEF SE9 - Interim Report Q2 January - June 2026
SEYE SMTEF SE9 - Interim Report Q2 January - June 2026
SPAGO.ST 7UX.F - Spago Nanomedical Interim Report January-June 2026
SPAGO.ST 7UX.F - Spago Nanomedical Interim Report January-June 2026
PG&E Q2 2026 Earnings Call: Complete Transcript
PG&E (NYSE: PCG ) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered APIs. For comprehensive financial data and transcripts, visit Access the full call at Summary PG&E reported core earnings per share of $0.40 for Q2 and $0.83 for H1 202
Creative Medical Technology Announces Its ADAPT Trial To Study Its CELZ-201 Is 85% Enrolled
Dear Fellow Shareholder: Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis ("OA"), immunotherapy, and biodefense. This progress, combined with disciplined capital allocation and expand